SM
CABA icon

SG3 Management’s Cabaletta Bio CABA Stock Holding History

SG3 Management’s Portfolio CABA Stock Details CABA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-5,100
Closed -$10K – 466
2022
Q1 		$10K Hold
5,100
– – ﹤0.01% 896
2021
Q4 		$19K Buy
+5,100
New +$54.4K ﹤0.01% 994
2021
Q2 		– Sell
-20,000
Closed -$222K – 1053
2021
Q1 		$222K Buy
+20,000
New +$244K 0.01% 944

Other funds holding CABA

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

SG3 Management's CABA Position: Q2 2022 in Review

SG3 Management sold out of Cabaletta Bio (CABA) in Q2 2022, closing a stake of 20,000 shares — an estimated $41K sold.

SG3 Management first reported a position in CABA in Q4 2021 and held it in 2 quarters. The position peaked at $76K in Q4 2021. 55 funds tracked by Wall St. Rank hold CABA as of Q2 2022.

  • SG3 Management reported no remaining Cabaletta Bio position as of Q2 2022 after selling out during the quarter.
  • SG3 Management sold 20,000 Cabaletta Bio shares in Q2 2022, an estimated $41K.
  • SG3 Management first reported a position in Cabaletta Bio in Q4 2021 and held it in 2 quarters.
  • SG3 Management's Cabaletta Bio position peaked at $76K in Q4 2021.
  • 55 funds tracked by Wall St. Rank held Cabaletta Bio as of Q2 2022.

Based on SG3 Management's 13F filing for Q2 2022, filed 15 Aug 2022.